RxSight Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
RXST$4.90+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Sales | $89,077 | $49,005 |
| Cost of sales | 35,312 | 27,677 |
| Gross profit | 53,765 | 21,328 |
| Operating expenses: | ||
| Selling, general and administrative | 74,799 | 58,665 |
| Research and development | 29,051 | 25,981 |
| Total operating expenses | 103,850 | 84,646 |
| Loss from operations | (50,085) | (63,318) |
| Other income (expense), net: | ||
| Interest expense | (3,308) | (4,946) |
| Interest and other income | 6,574 | 1,517 |
| Loss on extinguishment of term loan | (1,769) | — |
| Loss before income taxes | (48,588) | (66,747) |
| Income tax expense | 20 | 9 |
| Net loss | $(48,608) | $(66,756) |
| Other comprehensive income (loss) | ||
| Unrealized gain (loss) on short-term investments | 83 | (66) |
| Foreign currency translation gain (loss) | 7 | (9) |
| Total other comprehensive income (loss) | 90 | (75) |
| Comprehensive loss | $(48,518) | $(66,831) |
| Net loss per share: | ||
| Basic & diluted | $(1.41) | $(2.41) |
| Weighted-average shares used in computing net loss per share: | ||
| Attributable to common stock, basic & diluted | 34,455,111 | 27,661,982 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.